GALENICUM is currently following a twofold strategy regarding in-licensing needs of the Laboratories
- Selling and management of National submissions and MRP procedures of companies represented by Galenicum
- Broad respiratory portfolio (i.e. Salbutamol, other combination inhalers, etc)
Oncology Portfolio both in solids and injectables
- Hormone and steroid
- Partnership alliances for development of new products, from pharmaceutical development up to submission stage
The combination of the products available from our partners combined with the products that result from alliances lets us cover most of the products needed today by the companies
Own development
- Galenicum has concluded already two developments of 2 of the biggest blockbusters. If you want more information please contact us
- We are engaged in three generic developments currently